Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER

References

• Abrams P, Cardozo L, Fall M, . The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61: 37–49
   PubMed Web of Science ®Google Scholar
• Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care 2000;6: S580–S590
   PubMed Web of Science ®Google Scholar
• Coyne KS, Payne C, Bhattacharyya SK, . The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004;7: 455–63
   PubMed Web of Science ®Google Scholar
• Currie CJ, McEwan P, Poole CD, . The impact of the overactive bladder on health-related utility and quality of life. Br J Urol Int 2006;97: 1267–72
   Google Scholar
• Grimby A, Milsom I, Molander U, . The influence of urinary incontinence on the quality of life of elderly women. Age Ageing 1993;22: 82–9
   PubMed Web of Science ®Google Scholar
• O'Conor RM, Johannesson M, Hass SL, Kobelt-Nguyen G. Urge incontinence. Quality of life and patients' valuation of symptom reduction. Pharmacoeconomics 1998;14: 531–9
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Kopp Z, . Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. Br J Urol Int 2006;97: 96–100
   Google Scholar
• Brown JS, Vittinghoff E, Wyman JF, . Urinary incontinence: does it increase risk for falls and fractures? [Study of Osteoporotic Fractures Research Group]. J Am Geriatr Soc 2000;48: 721–5
   PubMed Web of Science ®Google Scholar
• Wagner TH, Hu TW, Bentkover J, . Health-related consequences of overactive bladder. Am J Manag Care 2002;8: S598–S607
   PubMed Web of Science ®Google Scholar
• Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000;6: S574–S579
   PubMed Web of Science ®Google Scholar
• Hu MK, Moore K, Suback L, . Abrams P, Koury S, Wein Aeditors. Economics of incontinence. Incontinence. Plymouth, UK: Health Publication Limited 2002
   Google Scholar
• Hu TW, Wagner TH. Health-related consequences of overactive bladder: an economic perspective. Br J Urol Int 2005;96(Suppl 1):43–5
   Google Scholar
• Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000;55: 33–46
   PubMed Web of Science ®Google Scholar
• Alhasso AA, McKinlay J, Patrick K, Stewart L. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006CD003193
   PubMed Web of Science ®Google Scholar
• Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 2000;48: 370–4
   PubMed Web of Science ®Google Scholar
• Cardozo L, Lisec M, Millard R, . Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172: 1919–24
   PubMed Web of Science ®Google Scholar
• Chapple CR, Arano P, Bosch JL, . Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. Br J Urol Int 2004;93: 71–7
   Google Scholar
• Chapple CR, Rechberger T, Al-Shukri S, . Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. Br J Urol Int 2004;93: 303–10
   Google Scholar
• Chapple CR. Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder. Expert Opin Pharmacother 2006;7: 2421–34
   PubMed Web of Science ®Google Scholar
• Chapple CR, Martinez-Garcia R, Selvaggi L, . A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48: 464–70
   PubMed Web of Science ®Google Scholar
• Garely AD, Kaufman JM, Sand PK, . Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther 2006;28: 1935–46
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Cardozo L, Chapple CR, . Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. Br J Urol Int 2005;95: 81–5
   Google Scholar
• Staskin DR, Dmochowski RR, Wein AJ. Solifenacin versus tolterodine – a head-to-head study: finally! But not final?. Curr Urol Rep 2005;6: 403–4
   PubMedGoogle Scholar
• Aceves C, Ferguson C, Seifeldin R, . Solifenacin improves overactive bladder symptoms and health-related quality of life in patients switching from tolterodine treatment due to residual urgency. Paper presented atThe Society of Urologic Nurses and Associates 2006 Annual Conference, October 27–30 2006;Kansas City, MO
   Google Scholar
• Forero-Schwanhaeuser S, Chancellor MB, Karram MM. Solifenacin treatment reduces symptoms of overactive bladder in patients with residual urgency on tolterodine treatment: results of the VERSUS study. Paper presented at The 76th Annual Meeting of the New England Section of the American Urological Association. Boston, MA, September 29 2007
   Google Scholar
• Shaya FT, Blume S, Gu A, . Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 2005;11: S121–S129
   PubMed Web of Science ®Google Scholar
• Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health 2005;8: 495–505
   PubMed Web of Science ®Google Scholar
• Noe L, Sneeringer R, Patel B, Williamson T. The implications of poor medication persistence with treatment for overactive bladder. Manag Care Interface 2004;17: 54–60
   PubMedGoogle Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4: 353–65
   PubMed Web of Science ®Google Scholar
• Furlong WJ, Feeny DH, Torrance GW, Barr RD. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med 2001;33: 375–84
   PubMed Web of Science ®Google Scholar
• Dallosso HM, McGrother CW, Matthews RJ, Donaldson MM. The association of diet and other lifestyle factors with overactive bladder and stress incontinence: a longitudinal study in women. Br J Urol Int 2003;92: 69–77
   Google Scholar
• Coyne KS, Matza LS, Thompson CL, . Determining the importance of change in the overactive bladder questionnaire. J Urol 2006;176: 627–32
   PubMed Web of Science ®Google Scholar
• Abrams P, Larsson G, Chapple C, Wein AJ. Factors involved in the success of antimuscarinic treatment. Br J Urol Int 1999;83(Suppl 2):42–7
   Google Scholar
• Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005;48: 5–26
   PubMed Web of Science ®Google Scholar
• Meyhoff HH, Gerstenberg TC, Nordling J. Placebo – the drug of choice in female motor urge incontinence?. Br J Urol 1983;55: 34–7
   PubMedGoogle Scholar